Patrick Burnett Sells 9,794 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 9,794 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $25.81, for a total transaction of $252,783.14. Following the sale, the insider owned 80,651 shares in the company, valued at $2,081,602.31. The trade was a 10.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Patrick Burnett also recently made the following trade(s):

• On Monday, February 2nd, Patrick Burnett sold 3,675 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.50, for a total transaction of $93,712.50.
• On Monday, January 5th, Patrick Burnett sold 2,490 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $28.98, for a total transaction of $72,160.20.
• On Wednesday, December 31st, Patrick Burnett sold 1,697 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $29.20, for a total transaction of $49,552.40.
• On Monday, December 15th, Patrick Burnett sold 11,500 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $28.94, for a total transaction of $332,810.00.
• On Thursday, November 6th, Patrick Burnett sold 17,250 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $24.18, for a total transaction of $417,105.00.

Arcutis Biotherapeutics Trading Down 0.0%

Shares of ARQT stock opened at $26.07 on Friday. The company has a current ratio of 3.50, a quick ratio of 3.28 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of -72.42 and a beta of 1.70. Arcutis Biotherapeutics, Inc. has a 12-month low of $11.13 and a 12-month high of $31.77. The stock’s 50-day moving average price is $28.13 and its 200-day moving average price is $22.46.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Analyst support remains constructive — multiple firms maintain Buy/outperform views and the consensus rating sits at a “Moderate Buy” with an average price target near $29.20, which can limit downside pressure. Read More.
• Positive Sentiment: Several institutional investors added or initiated positions in Q4 (examples: Independent Advisor Alliance, Virginia Retirement Systems, Trek Financial, RFG Advisory), indicating fresh demand from funds that could support the stock. Read More.
• Neutral Sentiment: Arcutis granted 94,000 restricted stock units to 12 newly hired employees under a Nasdaq inducement rule — a sign of hiring/expansion but also a small potential dilution source; impact is likely minor. Read More.
• Neutral Sentiment: Reported short-interest data appears anomalous (effectively zero in recent reporting) and is unlikely to be a meaningful immediate catalyst; treat the reading with caution. Read More.
• Negative Sentiment: Clustered insider selling — multiple executives and a director disclosed sales on Feb. 2–4, totaling sizeable transactions and >$1M in proceeds. Notable filings include Masaru Matsuda (40,638 shares at ~$25.28), Todd Watanabe (19,833 at ~$25.50), Director Howard Welgus (10,000 at ~$25.05) and CFO Latha Vairavan (1,320 at ~$25.50). Concentrated insider sales can amplify short-term negative sentiment and weigh on the stock. Read More.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ARQT shares. Wall Street Zen lowered shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Mizuho boosted their target price on shares of Arcutis Biotherapeutics from $32.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, November 28th. Zacks Research lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Needham & Company LLC upped their price objective on Arcutis Biotherapeutics from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, The Goldman Sachs Group lifted their target price on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.20.

Institutional Investors Weigh In On Arcutis Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ARQT. Johnson Investment Counsel Inc. purchased a new stake in Arcutis Biotherapeutics in the third quarter worth $30,000. SBI Securities Co. Ltd. lifted its holdings in Arcutis Biotherapeutics by 325.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock valued at $32,000 after buying an additional 833 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Arcutis Biotherapeutics by 10.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,828 shares of the company’s stock valued at $124,000 after buying an additional 820 shares in the last quarter. Jones Financial Companies Lllp boosted its position in Arcutis Biotherapeutics by 1,291.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 7,067 shares of the company’s stock valued at $124,000 after buying an additional 6,559 shares during the period. Finally, Atlas Wealth LLC bought a new position in Arcutis Biotherapeutics in the 2nd quarter worth about $138,000.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.